In an unexpected result, researchers found lung and skin cancer patients who had received Covid-19 vaccines experienced significantly increased survival times when compared with those who were ...

Two abstracts accepted for presentation One abstract on new additional biomarker and immunogenicity data for personalized cancer vaccine EVX-01 Another abstract on the use of Evaxion’s AI-Immunology™ ...

TACTI-004 planned ~756 patients across >150 sites and enrolled 378 by February 2026, including squamous and nonsquamous NSCLC irrespective of PD-L1 status. Randomization compared eftilagimod alfa plus ...

Merck & Co., Inc. (NYSE:MRK) is included among the 15 Best Safe Dividend Stocks for 2026. On March 12, Wells Fargo raised its ...

Stocktwits activity surged after the NCCN update, with message volumes jumping over 300% in 24 hours. ・Retail traders flagged bullish calls on revenue growth and “generational wealth” in response to ...

Announced Positive Data from Phase 1 Dose Expansion Study of varsetatug masetecan ("Varseta-M") EpCAM PROBODY(R) ADC in Patients with Advanced Colorectal Cancer (CRC) - - FDA interactions targeted for ...

AstraZeneca's cancer immunotherapy Imfinzi has been approved in the EU for use before and after surgery for early-stage ...

With no biology degree and just $3,000, he designed a personalized mRNA vaccine in a world first. Moderna and Merck are ...

The company will now assess the available data to determine its next steps in progressing efti’s development across multiple solid tumour indications.

Pembrolizumab plus weekly paclitaxel, with investigator-choice bevacizumab, achieved statistically significant PFS and OS improvements, addressing a high unmet need in platinum-resistant ovarian ...

Immutep and the Australian biotech’s investors have been caught off guard by the unexpected failure of its LAG-3 candidate in a phase 3 study. | Immutep and the Australian biotech’s investors have ...